27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Meridian Bioscience (NASDAQ:VIVO) moved higher by 5.5% in pre-market trading after the company reported Q1 results.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Quarterly Results
Earnings per share increased 550.00% year over year to $0.65, which beat the estimate of $0.42.
Revenue of $92,917,000 higher by 95.94% year over year, which beat the estimate of $83,890,000.
Guidance
The upcoming fiscal year's EPS expected to be between $1.70 and $1.90.
The upcoming fiscal year's revenue expected to be between $320,000,000 and $350,000,000.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Details Of The Call
Date: Feb 05, 2021
Time: 10:00 AM
ET Webcast URL: https://investor.meridianbioscience.com/events/event-details/q1-2021-financial-results-conference-call
Price Action
52-week high: $26.58
Company's 52-week low was at $5.51
Price action over last quarter: Up 38.12%
Company Profile
Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.